Anna D. Garrett, PharmD, BCPS, CPP
Published Online: Friday, December 1, 2006

Canadian researchers have found that adding warfarin to aspirin therapy in peripheral arterial disease (PAD) adds no therapeutic benefit relative to cardiovascular (CV) events but greatly increases the number of life-threatening bleeds. This large study of 2000 patients in 7 countries randomized patients to receive aspirin alone or aspirin and warfarin titrated to an international normalized ratio of 1.8 to 3.5. None of the primary end points (CV death, myocardial infarction, stroke, and severe ischemia) showed any significant benefit in favor of the combination. The combination therapy in PAD, however, resulted in a significant increase in life-threatening and moderate bleeds, including a 15-fold increase in the risk of hemorrhagic stroke.

Dr. Garrett is a clinical pharmacist practitioner at Cornerstone Health Care in High Point, NC.

Latest Articles
A pharmacy robber not only left his fingerprints behind at a pharmacy—he also dropped his wallet containing his identification as he made his escape.
Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).
Treating chronic pulmonary obstructive disease with both inhaled corticosteroids and long-acting bronchodilators remains controversial, but new evidence suggests that this controller combination could reduce mortality risk.
Beverly Schaefer, RPh, of Katterman's Sand Point Pharmacy in Seattle, Washington, shares some fun tips on how to encourage patients who travel to come to your pharmacy for supplies.
Latest Issues